The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Amivantamab for EGFR Exon 20 Insertion Mutant Lung Cancer: EGFR-MET Bispecific Antibody

Novel bispecific antibody addressing previously untargetable EGFR exon 20 insertion mutations in NSCLC

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Amivantamab for EGFR Exon 20 Insertion Mutant Lung Cancer: EGFR-MET Bispecific Antibody?

Amivantamab is fully human IgG1 bispecific antibody binding to extracellular domains of both EGFR and MET receptors.

EGFR exon 20 insertions represent heterogeneous family of mutations producing receptor activation but resistance to traditional EGFR TKIs.

MET targeting addresses common bypass mechanism in EGFR-driven cancers including amplification, mutation and overexpression.

FDA approval is for locally advanced or metastatic NSCLC with EGFR exon 20 insertion after platinum-based chemotherapy.

Activity also extends to EGFR-mutant NSCLC progressing on tyrosine kinase inhibitors though approval status varies by indication.

Symptoms

Infusion reactions occur in majority of patients particularly during first infusion requiring premedication and split-dose administration.
Acneiform skin rash characteristic of EGFR inhibition affects most patients requiring dermatologic management.
Paronychia, dry skin and hair changes from EGFR inhibition require ongoing skin and nail care.
Hypoalbuminemia, peripheral edema and venous thromboembolism risk require monitoring and management.
Interstitial lung disease and pneumonitis represent serious adverse events requiring vigilant respiratory monitoring.

Risk Factors

Pre-existing pulmonary disease, prior chest radiation or smoking history may affect tolerability and ILD risk.
History of thromboembolism increases venous thromboembolism risk requiring prophylactic anticoagulation consideration.
Severe skin conditions including pre-existing dermatitis may worsen with EGFR-targeted therapy.
Performance status, prior therapies and disease burden affect treatment selection and dose modifications.
Drug interactions with CYP3A4 inhibitors and inducers require concomitant medication assessment.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • EGFR-mutant NSCLC progression on TKI therapy or specific exon 20 insertion mutations warrant amivantamab consideration.
  • Comprehensive molecular profiling at progression including DNA and RNA sequencing identifies actionable alterations.
  • Severe infusion reactions during treatment require treatment interruption, supportive care and modified rechallenge approaches.
  • Significant skin toxicity, paronychia or other dermatologic effects require ongoing dermatologic management and dose modifications.
  • New respiratory symptoms warrant prompt evaluation excluding pneumonitis with imaging and pulmonary consultation.

Treatment Methods

01
Standard dosing weight-based with 1050 mg if less than 80 kg or 1400 mg if 80 kg or more weekly for first 4 weeks then every 2 weeks.
02
First infusion split-dose administration with premedication including antihistamines, corticosteroids and acetaminophen.
03
Pre-emptive skin care with moisturizers, sunscreen and topical antibiotics manages anticipated EGFR-related toxicity.
04
Venous thromboembolism prophylaxis with anticoagulation consideration in higher-risk patients during treatment.
05
Comprehensive supportive care, dermatologic management, infusion reaction protocols and patient education supports successful administration of this innovative bispecific antibody addressing a historically challenging EGFR mutation subtype.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.